AbbVie Inc. (ABBV) Stock: Dips Despite $2.54 Billion Disco Cancer Deal

In this news:

Key takeaways

  • AbbVie shares fell 0.60% to $284.25 despite a cancer research deal with Disco Pharmaceuticals.
  • Disco receives $40 million upfront and could earn $2.5 billion in milestone payments.
  • The partnership targets solid tumors with next-generation bispecific antibodies.
  • AbbVie (ABBV) shares fell 0.60% to $284.25 despite the $2.54B Disco cancer deal.
  • Disco will receive $40M upfront and could earn $2.5B in milestone payments.
  • The partnership targets solid tumors using next-generation bispecific antibodies.
  • Disco will lead drug discovery, while AbbVie can license selected programs.
  • Disco expects to select a cancer drug candidate in the second half of 2027.

AbbVie Inc. (ABBV) stock declined 0.60% to $284.25, losing $1.71 despite announcing a major cancer research agreement. The pharmaceutical company partnered with Germany-based Disco Pharmaceuticals in a deal worth up to $2.54 billion. The collaboration expands AbbVie’s cancer pipeline through new antibody treatments targeting difficult-to-treat solid tumors.

AbbVie stock slips despite $2.54 billion cancer partnership

AbbVie shares faced early selling pressure after closing the previous session at $285.96. Meanwhile, the company secured access to Disco’s research platform through a new option-to-license agreement. The partnership strengthens AbbVie’s efforts to develop targeted cancer medicines.

Under the agreement, Disco will receive $40 million upfront and potentially $2.5 billion in additional milestone payments. The payments depend on licensing decisions, development progress, and other agreed conditions. Disco could also earn tiered royalties from worldwide sales of resulting treatments.

The companies will focus on AND-gated bispecific antibodies for solid tumors with significant medical needs. These treatments recognize cancer cells through two specific proteins appearing together. This approach aims to improve tumor targeting while reducing damage to healthy tissue.

Disco Pharmaceuticals to lead early cancer drug research

Disco will manage initial research and discovery using its proprietary DiscoTech platform. The technology maps proteins on cancer cell surfaces to identify suitable treatment targets. AbbVie will contribute its expertise in cancer biology and target selection.

Following the research phase, AbbVie can exercise exclusive licensing options for selected development programs. However, neither company disclosed the number of programs covered by the agreement. Both companies also withheld specific timelines for clinical development.

Disco currently researches potential treatments for small-cell lung cancer and colorectal cancer. The company expects to select a development candidate during the second half of 2027. Meanwhile, its collaboration with AbbVie supports further research into precision cancer treatments.

AbbVie expands cancer pipeline amid growing industry competition

AbbVie has continued expanding its presence in bispecific antibody treatments through major pharmaceutical partnerships. In January, the company paid RemeGen $650 million upfront for rights outside China. That agreement covered a bispecific cancer treatment targeting solid tumors.

Other pharmaceutical companies have also committed substantial funding to similar cancer research programs. Bristol Myers Squibb partnered with BioNTech in an agreement worth up to $11.1 billion. Meanwhile, UCB acquired Candid Therapeutics for $2.2 billion, reflecting continued industry interest.

AbbVie’s latest agreement adds another early-stage program to its expanding oncology portfolio. The milestone-based structure spreads potential payments across future research and development achievements. However, the collaboration must advance through drug discovery and clinical testing before generating commercial revenue.

Source: blockonomi.com

Share the article:

Top Trending Cryptocurrencies on The Market

Current Price

$0.005122

7 Days
FLR 7 days: -2.77%

Market Cap

$450.0M -1.24%

24h Volume

$2.7M

Supplies

107.0B / ∞

Current Price

$0.05637

7 Days
PYTH 7 days: -10.97%

Market Cap

$443.9M 5.15%

24h Volume

$29.0M

Supplies

10.0B / 10.0B

Current Price

$0.9993

7 Days
YLDS 7 days: +0.01%

Market Cap

$432.8M -4.61%

24h Volume

$22.4M

Supplies

433.1M / ∞

Current Price

$0.004832

7 Days
VET 7 days: -3.75%

Market Cap

$415.5M -1.24%

24h Volume

$6.5M

Supplies

86.0B / 86.7B

Current Price

$0.02307

7 Days
STABLE 7 days: -16.49%

Market Cap

$415.2M 0.04%

24h Volume

$6.5M

Supplies

100.0B / 100.0B

Current Price

$0.006479

7 Days
HASH 7 days: -13.98%

Market Cap

$391.2M -13.38%

24h Volume

$3.6K

Supplies

95.0B / 100.0B

Current Price

$0.9989

7 Days
SOFID 7 days: +0.03%

Market Cap

$376.4M -0.64%

24h Volume

$15.9M

Supplies

376.8M / ∞

Current Price

$0.4227

7 Days
APT 7 days: -20.01%

Market Cap

$375.9M -2.51%

24h Volume

$27.7M

Supplies

1.2B / 2.1B

Current Price

$1.390

7 Days
RAY 7 days: -9.76%

Market Cap

$375.3M -1.04%

24h Volume

$14.1M

Supplies

555.0M / 555.0M

Current Price

$0.04453

7 Days
9BIT 7 days: +0%

Market Cap

$365.1M 5.92%

24h Volume

$8.0M

Supplies

10.0B / 10.0B

Current Price

$1.110

7 Days
REUSD 7 days: +0.09%

Market Cap

$362.5M -0.27%

24h Volume

$2.9M

Supplies

325.6M / ∞

Current Price

$0.1012

7 Days
FF 7 days: +21.55%

Market Cap

$358.8M 0.58%

24h Volume

$6.6M

Supplies

10.0B / 10.0B

Notifications Login to see

Today

No Notifications

↑